Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

New research suggests popular weight loss drugs like Ozempic and Wegovy may affect more than just fat, raising questions about muscle strength and organ size after significant weight loss. University ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Researchers have found a potential game-changing way to help people lose weight and control blood sugar without the ...